Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (With 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety

NCT07048808 is registered in ClinicalTrials.gov with XyloCor Therapeutics, Inc. as lead sponsor.

NCT NCT07048808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07048808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (With 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety
Lead sponsor
XyloCor Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 8, 2025
Completion date
December 30, 2027
Enrollment
106 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, refractory angina